share_log

HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $1.5

HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $1.5

HC Wainwright & Co. 維持對x4製藥的買入評級,目標價格下調至1.5美元
Benzinga ·  11/14 10:09  · 評級/大行評級

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $5 to $1.5.

HC Wainwright & Co. 分析師Swayampakula Ramakanth維持X4製藥公司(納斯達克股票代碼:XFOR)的買入並將目標股價從5美元下調至1.5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論